Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
Recruiting · NCT02521311 · Registry updated 2026-03-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER) | CNS demyelinating autoimmune disease, Eye Manifestations, Eye Pain, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, cranial nerve neuropathy, demyelinating disease, eye disorder, immune system disorder, multiple sclerosis, nervous system disorder, optic nerve disorder, optic neuritis, vision disorder | Recruiting | Phase 2 | 2026-03-11 | NCT02521311 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Moorfields Eye Hospital NHS Foundation Trust | 11 |
| University of California, San Francisco | 637 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of California San Francisco | San Francisco | United States | 80 |